（百诚医药公告） 近日，百诚医药发布公告称，公司与浙江众神创新医药科技有限公司（以下简称"众神创新"）就1类创 新药BIOS-0629项目达成大中华地区（大陆及港澳台地区）独家授权合作并签署了《技术开发合作协 议》及补充协议，合作协议自公司股东大会审议通过后生效。 众神创新的法定代表人和高级管理人员冯恩光先生为百诚医药原副总经理，其于2025年2月7日不再担任 百诚医药该职务并于6月离职。根据《深圳证券交易所创业板股票上市规则》（以下简称"《上市规 则》"），过去十二个月内担任公司高级管理人员的人员为上市公司关联自然人，因冯恩光先生目前在 众神创新担任高级管理人员，众神创新为公司的关联法人。因此公司与众神创新的本次交易构成关联交 易。 ...

在随后召开的2025北京."生命谷"医药数智化赋能生命健康之路研讨会上，与会专家聚焦"数智化赋能生 命健康"这一前沿议题，围绕人工智能助力公立医院高质量发展、AI重塑医药研发、计算医学驱动虚拟 临床试验等主题进行分享。高校、科研院所、行业协会、金融机构及企业代表参加活动。 新京报讯11月22日，以"智绘生命创领未来"为主题的生命谷(国际)生物工程创新中心启动大会暨2025北 京."生命谷"医药数智化赋能生命健康之路研讨会举行。中国卫生经济学会会长、国家卫生健康委财务 司原司长何锦国，昌平实验室党委副书记朱建红，区委书记、未来科学城党工委书记甘靖中，区委副书 记、区长，未来科学城党工委副书记、管委会主任刘晓东，北京农学院党委常委、副院长张劲柏出席。 据悉，生命谷(国际)生物工程创新中心是中国生命科学与未来产业前沿技术成果转化的战略首站，将聚 焦细胞与基因治疗、AI医疗等前沿赛道，锚定人工智能、电子信息、半导体等，形成"研发-中试-产业 化"全生命周期的生态闭环。这里汇聚全球顶尖科研资源与产业链上下游企业，依托国家级平台和临床 资源，将成为生物工程领域创新突破与成果转化的首选高地，为北京国际科技创新中心建设贡献" ...

公告显示，此次合作由百诚医药负责合作产品的研究开发工作、临床试验、注册申报等工作。众神创新 负责大中华区域的研发转化、上市后生产销售和市场拓展工作。本合同签署后，众神创新根据研发节点 支付里程碑款3亿元。合作产品在大中华区上市后，公司另享有销售额10%的提成收益。 （文章来源：北京商报） 北京商报讯（记者丁宁）11月21日晚间，百诚医药（301096）发布公告称，公司与浙江众神创新医药科 技有限公司（以下简称"众神创新"）就1类创新药BIOS-0629项目达成大中华地区（大陆及港澳台地区） 独家授权合作并签署了《技术开发合作协议》及补充协议，合作协议自公司股东大会审议通过后生效。 ...

百诚医药（301096）(301096.SZ)公告，公司与浙江众神创新医药科技有限公司(简称"众神创新")就1类 创新药BIOS-0629项目达成大中华地区独家授权合作并签署了《技术开发合作协议》及补充协议。 关于BIOS-0629项目研发进度，目前处于PCC阶段，其适应症为：实体瘤。根据协议，公司将负责合作 产品的研究开发工作、临床试验、注册申报等工作。众神创新负责大中华区域的研发转化、上市后生产 销售和市场拓展工作。合同签署后，众神创新根据研发节点支付里程碑款3亿元。合作产品在大中华区 上市后，公司另享有销售额10%的提成收益。 公告称，此次合作，双方将依托各自在创新药研发领域的资源与技术优势，深化协同创新，加速BIOS- 0629项目从实验室成果向临床应用的转化进程，共同推动创新成果。 ...

百诚医药公告，公司与浙江众神创新医药科技有限公司就1类创新药BIOS-0629项目达成大中华地区 （大陆及港澳台地区）独家授权合作并签署了《技术开发合作协议》及补充协议，合作协议自公司股东 大会审议通过后生效。交易价格为人民币3亿元。众神创新的法定代表人和高级管理人员冯恩光先生为 公司原副总经理，因此公司与众神创新的本次交易构成关联交易。 ...

Core Viewpoint - The company emphasizes the importance of innovation in drug development for oncology, autoimmune diseases, and neurobiology, highlighting unmet clinical needs and market demand in these areas [1] Group 1: Oncology - Oncology remains a key focus in innovative drug development, with increasing resistance leading to ongoing breakthroughs in immunotherapy, targeted therapy, and personalized medicine [1] - There is a persistent unmet clinical demand in the oncology sector, indicating potential investment opportunities [1] Group 2: Autoimmune Diseases - Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are significant areas of interest for biopharmaceutical companies [1] - These diseases predominantly affect the younger workforce, and there is a high demand for effective treatments due to poor treatment outcomes and medication adherence [1] Group 3: Neurobiology - Neurodegenerative diseases like Alzheimer's, Parkinson's, and diabetic neuropathy are gaining attention from global pharmaceutical companies and research institutions [1] - The aging global population is contributing to a rapid increase in the number of patients with neurodegenerative diseases, creating substantial market demand [1] Group 4: Company Performance - For the period from January to September 2025, the company reported revenue of 510 million yuan, a year-on-year decrease of 29.33% [1] - The net profit attributable to the parent company was 6 million yuan, reflecting a significant year-on-year decline of 95.68% [1] Group 5: Drug Development Pipeline - The company has established multiple self-developed drug pipelines in neurobiology, autoimmune diseases, and oncology [1] - It has obtained three IND approvals for Class I new drugs and ten IND approvals for Class II new drugs, indicating progress in its drug development efforts [1]

Core Viewpoint - The company Hualan Co., Ltd. is entering the AI innovative drug development sector through its subsidiary Lingqing Zhizhi, aiming to leverage its existing client base in pharmaceutical packaging to create synergies and explore new growth opportunities [1][5]. Group 1: Investment and Partnerships - Lingqing Zhizhi has signed a capital increase agreement with several companies, including Shenzhen Jingtai and XtalPi, to invest in Kema Biotechnology [1][4]. - The company plans to invest 20 million yuan to acquire a 9.53% stake in Kema Biotechnology, which will also grant it a board seat and priority acquisition rights [3][4]. Group 2: Industry Context - Kema Biotechnology, founded in 2021, focuses on antibody design using generative AI models, aiming to innovate the traditional methods of antibody discovery [4]. - The AI innovative drug development sector is gaining attention as it offers a potential solution to the lengthy and costly traditional drug development process, which typically requires ten years and one billion dollars to develop a new drug [4]. Group 3: Business Strategy and Performance - Hualan Co., Ltd. is committed to enhancing its capabilities in AI innovative drug development by attracting top industry experts and building a diverse business team [4]. - In the first three quarters of the year, the company reported a revenue of 441 million yuan, a year-on-year increase of 4.36%, but experienced a decline in revenue and net profit in the third quarter [7].

Core Insights - The "2025 China Health Industry Development and Rehabilitation Service Conference" will focus on technological innovation in the health sector, aligning with the "14th Five-Year Plan" to enhance self-reliance in health technology [2][5] - The health industry in China has seen significant growth, expanding from 7.4 trillion yuan to 12.3 trillion yuan over five years, with advancements in AI medical applications and CAR-T therapies [2][5] Academic Leadership - The conference will feature prominent academic figures, including academician Fan Daiming, who will discuss integrated medicine and its relevance to the "14th Five-Year Plan" [5][6] - Fan's presentation will focus on breakthroughs in the diagnosis and treatment of digestive diseases, emphasizing the importance of integrated prevention and management [5][6] Industry Practices - Over 50 leading companies from various sectors of the health industry will participate, covering innovative drug development, medical devices, healthcare services, health management, and digital health [8][9] - The conference will include roundtable discussions addressing key industry issues, such as investment opportunities in innovative drugs and the commercialization of brain-computer interfaces [9][10] Innovation and Collaboration - The event will facilitate direct interactions between experts and companies to address technological challenges and foster collaboration [6][12] - A showcase area will feature over 20 representative companies displaying their latest technologies and core products, enhancing visibility for industry innovations [12][13] Authoritative Results and Reports - The conference will release significant reports, including the "2025 China Health Industry White Paper" and the "Hua Xia ESG Dandelion 50-30 Index 2025 Annual Report," providing valuable insights and benchmarks for the industry [13][15] - The ESG report will evaluate 50 A-share companies and 30 H-share growth companies based on environmental, social, and governance criteria, supporting sustainable development in the health sector [13][15] Future Directions - The conference aims to create a continuous service platform for the health industry, ensuring that innovative practices and authoritative findings are effectively implemented [16][17] - The event will gather experts, industry leaders, and investment representatives to collaboratively shape the future of the health industry in China [16][17]

Core Viewpoint - The company, Borui Pharmaceutical, announced an investment of 50 million yuan in Suzhou Geek Gene Technology, increasing its stake from 4.0816% to 12.8015% [2] Group 1: Investment Details - The investment includes a subscription to the new registered capital of 437,100 yuan, with the remaining amount allocated to the capital reserve of Geek Gene [2] - This investment aligns with the company's innovation-driven development strategy [2] Group 2: Strategic Implications - The collaboration is expected to leverage both companies' strengths in innovative drug development and cell therapy technology [2] - Geek Gene possesses unique technological advantages in areas such as cell fate reprogramming and low-cost high-throughput omics technology, which may create potential synergies with the company's product development [2]

灵擎数智与深圳晶泰拟共同向科迈生物进行增资入股。其中，灵擎数智计划使用自有资金人民币2,000 万元认购科迈生物新增的注册资本，进一步取得本次交易后科迈生物基于完全摊薄基础上9.53%的股权 (对应于本次交易完成后科迈生物人民币296,296元的注册资本，剩余计入科迈生物资本公积)。 公告称，全球AI创新药研发领域正蓬勃发展，在这一趋势下，中国也亟需培育具备国际竞争力的本土 AI创新药研发企业，以积极参与全球医药创新的新一轮竞争。《中共中央关于制定国民经济和社会发 展第十五个五年规划的建议》，明确深入推进数字中国建设，全面实施"人工智能+"行动。本次对外投 资系华兰股份响应国家战略、进入AI创新药研发领域战略布局落地的一步。 华兰股份（301093）(301093.SZ)发布公告，华兰股份全资子公司灵擎数智于近日与深圳晶泰、XtalPi、 晶泰智启、科迈生物、科迈数抗以及持股平台签署了增资协议。同时，灵擎数智与深圳晶泰、科迈生 物、科迈数抗、持股平台、XtalPi、晶泰智启、百奥赛图、Duckling、 Vibrant签署了股东协议。 科迈生物成立于2021年，是由全球领先AI创新药研发企业—晶泰控股孵化的一 ...